Get started
BioNTech SE Sponsored ADRBioNTech SE Sponsored ADRBioNTech SE Sponsored ADR

BioNTech SE Sponsored ADR

No trades
See on Supercharts
Overview
Financials News Discussions Forecast Seasonals

22UA chart


Full chart

22UA upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪20.66 B‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.34 EUR
Net income (FY)
‪−695.17 M‬ EUR
Revenue (FY)
‪2.87 B‬ EUR
Shares float
‪236.73 M‬
Beta (1Y)
1.11

About BioNTech SE Sponsored ADR


Sector
Health Technology
Industry
Biotechnology
CEO
Ugur Sahin
Website
biontech.de
Headquarters
Mainz
Founded
2008
ISIN
US09075V1026
FIGI
BBG00QJ27RQ2
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Check out other big names from the same industry as 22UA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

22UA news



Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Sparks


Curated watchlists where 22UA is featured.

See all sparks